Patents by Inventor Jutta Wanner

Jutta Wanner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thiazolopyrimidine compounds
    Patent number: 8921383
    Abstract: The present invention relates to the use of novel thiazolopyrimidine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: December 30, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Cornelius Hermann, Lee Edwin Lowrie, Jr., Matthew C. Lucas, Kin-Chun Thomas Luk, Fernando Padilla, Jutta Wanner, Wenwei Xie, Xiaohu Zhang
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20140303149
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: April 2, 2014
    Publication date: October 9, 2014
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Andreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • Substituted pyrrolo[1,2-a]pyrazines as tankyrase inhibitors
    Patent number: 8841299
    Abstract: There are provided compounds of the formula wherein R1 and R2 are as described herein. The compounds are useful as anticancer agents.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: September 23, 2014
    Assignee: Genentech, Inc.
    Inventors: Johannes Hermann, Ann Catherine Petersen, Jutta Wanner, Lin Yi
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 8729078
    Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: May 20, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Joseph Billedeau, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou, Timothy D. Owens, Yimin Qian, Sung-Sau So, Kshitij C. Thakkar, Jutta Wanner, Omar Jose Morales
  • PYRROLOPYRAZONE INHIBITORS OF TANKYRASE
    Publication number: 20130345226
    Abstract: There are provided compounds of the formula wherein R1 and R2 are as described herein. The compounds are useful as anticancer agents.
    Type: Application
    Filed: June 19, 2013
    Publication date: December 26, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Hermann, Ann Catherine Petersen, Jutta Wanner, Lin Yi
  • TRIAZOLOPYRIDINE COMPOUNDS
    Publication number: 20120309746
    Abstract: The present invention relates to the use of novel triazolopyridine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Application
    Filed: May 24, 2012
    Publication date: December 6, 2012
    Inventors: Johannes Cornelius Hermann, Matthew C. Lucas, Kin-Chun Thomas Luk, Fernando Padilla, Jutta Wanner, Wenwei Xie, Xiaohu Zhang
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20120295885
    Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 22, 2012
    Inventors: Roland Joseph Billedeau, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou, Timothy D. Owens, Yimin Qian, Sung-Sau So, Kshitij C. Thakkar, Jutta Wanner
  • THIAZOLOPYRIMIDINE COMPOUNDS
    Publication number: 20120252777
    Abstract: The present invention relates to the use of novel pyrrolopyrazine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Application
    Filed: March 26, 2012
    Publication date: October 4, 2012
    Inventors: Johannes Cornelius Hermann, Lee Edwin Lowrie, JR., Matthew C. Lucas, Kin-Chun Thomas Luk, Fernando Padilla, Jutta Wanner, Wenwei Xie, Xiaohu Zhang
  • PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
    Publication number: 20120015962
    Abstract: Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
    Type: Application
    Filed: July 12, 2011
    Publication date: January 19, 2012
    Inventors: Nidhi Arora, Shaoqing Chen, Johannes Cornelius Hermann, Adreas Kuglstatter, Sharada Shenvi Labadie, Clara Jeou Jen Lin, Matthew C. Lucas, Amy Geraldine Moore, Eva Papp, Francisco Xavier Talamas, Jutta Wanner, Yansheng Zhai
  • HETEROCYCLIC ANTIVIRAL COMPOUNDS
    Publication number: 20110070190
    Abstract: The invention discloses 1-N-substituted-6-(hetero)aryl-1H-thieno[3,2-d]pyrimidin-4-one derivatives of formula wherein R1, R2, R3 and R4 are as defined herein that inhibit Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Application
    Filed: September 24, 2010
    Publication date: March 24, 2011
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, Robert Than Hendricks, Hans Maag, David Bernard Smith, Jutta Wanner
  • Octahydro-pyrrolo[3,4-c]pyrrole CCR5 receptor antagonists
    Patent number: 7625905
    Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: December 1, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Remy Lemoine, Chris Richard Melville, David Mark Rotstein, Jutta Wanner
  • Heterocyclic antiviral compounds
    Publication number: 20090028818
    Abstract: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPR.
    Type: Application
    Filed: July 24, 2008
    Publication date: January 29, 2009
    Inventors: Stephen Deems Gabriel, Remy Lemoine, David Mark Rotstein, Jutta Wanner
  • Heterocylic antiviral compounds
    Publication number: 20080103125
    Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
    Type: Application
    Filed: September 18, 2007
    Publication date: May 1, 2008
    Inventors: Remy Lemoine, Chris Melville, David Rotstein, Jutta Wanner
  • Heterocylic antiviral compounds
    Publication number: 20070191335
    Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 R6c and X1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV-1) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treating diseases mediated by the CCR5 receptor.
    Type: Application
    Filed: February 15, 2007
    Publication date: August 16, 2007
    Inventors: Remy Lemoine, Chris Melville, David Rotstein, Jutta Wanner
  • Heterocyclic antiviral compounds
    Publication number: 20070191406
    Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 R6c and X1 are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.
    Type: Application
    Filed: February 15, 2007
    Publication date: August 16, 2007
    Inventors: Rcmy Lemoine, Chris Melville, Fernando Padilla, David Rotstein, Jutta Wanner